<DOC>
	<DOCNO>NCT00481091</DOCNO>
	<brief_summary>The Phase 1 portion study evaluate pharmacokinetic profile safety ABT-263 two different dose schedule objective define dose limit toxicity maximum tolerate dose . The Phase 2a portion study evaluate ABT-263 define recommended Phase 2 dose obtain additional safety information preliminary assessment efficacy . The Extension Study portion allow active subject continue receive ABT-263 7 year last subject transition less frequent study evaluation .</brief_summary>
	<brief_title>A Phase 1/2a Study ABT-263 Subjects With Relapsed Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<criteria>Relapsed refractory Chronic Lymphocytic Leukemia require treatment opinion investigator Eastern Cooperative Oncology Group ( ECOG ) &lt; = 1 Adequate bone marrow independent growth factor support , renal hepatic function per define laboratory criterion History clinically suspicious cancerrelated Central Nervous System disease Receipt allogenic autologous stem cell transplant Recent history ( within 1 year first dose ) underlying , predispose condition bleed currently exhibit sign bleed Active peptic ulcer disease potentially hemorrhagic esophagitis/gastritis Active immune thrombocytopenic purpura history refractory platelet transfusion ( within 1 year first dose )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>